Australia's most trusted source of pharma news
Tuesday, 20 November 2018
Lost Your Access?
Drug expansions surging
But new approvals slow as 2018 draws to a close.
Keytruda adds blood tick
Picks up lymphoma in time for PBAC decision.
Biogen MD applauds patients
Tells summit their vioce is as important as trial data.
Amgen on gender roundtable
MD joins high-level government advisory board.
AZ prepares for Fasenra
Building salesforce despite PBS hurdle still to overcome.
AZ appoints new CE director
Novartis and Baxter make staff changes as well.
Job growth winners and losers
Who added, who cut in 2017-18 and by how much.
Pfizer CBD move delayed
Exclusive first pics of new city digs show not yet ready.
Pharma hits pay gap roadblock
Better than most Aust sectors but progress has stalled.
PBS 2018 newbies start big
New and expanded listings rack up $180m to Q3.
Govt supports drug repurposing
And faster PBAC/MSAC co-dependent assessments.
Cash for rare disease lobby
Govt stumps up close to $200K for Rare Voices Australia.
Allergan backs glaucoma group
Big grant to cover education, early detection and support.
Maviret makes its mark
Newcomer already impacting PBS Hep C market.
Pfizer's Lyrica patent pain
UK judgement could open way to $900 million payback.
Kidney drug gets competition
Dr Reddy's registers first non-originator brand of sevelamer.
US, EU moves in COPD
Mylan enters market as GSK expands presence.
PBAC status quo threatened
Committee changes come at crucial time.
Events & Conferences
© 2003 - 2018 Lush Media
Pharma in Focus
Jolly Good Design